2022 年
1. Manresa M, Miki H, Miller J, Okamoto K, Dobaczewska K, Herro R, Gupta RK, Kurten R,Aceves S , Croft M:
Deficiency in the Cytokine TNFSF14/LIGHT Limits Inflammation and Remodeling in Murine
Eosinophilic Esophagitis.
J Immunol. 209 (12): 2341–2351,2022
2. Yagishita M, Tsuboi H, Kuroda Y, Sawabe T, Kawashima A, Kawashima F, Uematsu N, SatoR, Nishiyama T, Terasaki M, Toko H, Honda F, Ohyama A, Abe S, Kitada A, Miki H, HagiwaraS, Kondo Y, Sumida T, Matsumoto I.:
Clinical features and serum cytokine profiles of elderly-onset adult-onset Still's disease.
Sci Rep. 12(1):21334,2022
3. Asashima H, Axisa PP, Pham THG, Longbrake EE, Ruff WE, Lele N, Cohen I, Raddassi K,
Sumida TS, Hafler DA.:
Impaired TIGIT expression on B cells drives circulating follicular helper T cell expansion inmultiple sclerosis.
J Clin Invest. 132(20):e156254,2022
4. Tsuboi H, Segawa S, Yagishita M, Toko H, Honda F, Kitada A, Miki H, Ohyama A, HagiwaraS, Kondo Y, Matsumoto I, Sumida T.:
Activation mechanisms of monocytes/macrophages in adult-onset Still disease.
Front Immunol. 13:953730,2022
5. Furuyama K, Kondo Y, Kaneko S, Shimizu M, Tanimura R, Tsuboi H, Sumida T, Matsumoto
I.:
Effecter Th17-like regulatory T cells associate with the pathogenesis of rheumatoid arthritis.
Rheumatology (Oxford). 62(1):e4-e6,2022
6. Konishi K, Nakamura K, Hanada Y, Kitanaga Y, Kubo S, Kinugasa F, Yamajuku D, Maeda M,Yamamoto N, Minematsu T, Ohbuchi M, Kondo Y, Sumida T.:
Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-linking Antibody, forPrediction of Human Pharmacokinetics and Clinically Effective Dose.
J Pharm Sci. 111(9):2630-2638,2022
7. Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H,

Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M,Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H,Kohsaka H.:
Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III,
multi-center, randomized controlled trial.
Rheumatology (Oxford). 61(11):4445-4454,2022
8. Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A, Tanaka R, Kubota N, Matsumoto
I, Ishii A, Tamaoka A, Shimbo A, Mori M, Morio T, Kishi T, Miyamae T, Tanboon J, Inoue M,
Nishino I, Fujimoto M, Nomura T, Okiyama N.:
Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory
myopathies is dependent on target protein properties.
J Dermatol. 49(4):441-447,2022
9. Aitake U, Ogawa T, Okune M, Kondo Y, Matsumoto I, Nomura T. :Multiple skin nodules on fingers in systemic lupus erythematosus.
Rheumatology (Oxford). 61(9):e296,2022
10. Adachi-Katayama M, Kondo Y, Okamoto S, Sato R, Morinaka S, Nishiyama T, Terasaki M,Terasaki T, Toko H, Yagishita M, Takahashi H, Hagiwara S, Tsuboi H, Sumida T, Matsumoto I. :Synovitis-acne-pustulosis-hyperostosis-osteitis Syndrome with Bilateral Pleural Effusion.Intern Med. 61(17):2671-2675,2022
11. Furuyama K, Kondo Y, Shimizu M, Yokosawa M, Segawa S, Iizuka A, Tanimura R, Tsuboi H,Matsumoto I, Sumida T.:
RORγt +Foxp3 + regulatory T cells in the regulation of autoimmune arthritis.
Clin Exp Immunol. 207(2):176-187,2022
12. Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A, Tanaka R, Kubota N, MatsumotoI, Ishii A, Tamaoka A, Shimbo A, Mori M, Morio T, Kishi T, Miyamae T, Tanboon J, Inoue M,Nishino I, Fujimoto M, Nomura T, Okiyama N.:
Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive
myositis without dermatomyositis-specific rash.
Rheumatology (Oxford). 61(3):1222-1227,2022